Announcements Trials

Browse Landscape

Phase

Status

Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Carcinoma, Non-Small-Cell Lung 55 Carcinoma, Hepatocellular 54 Lung Neoplasms 32 Small Cell Lung Carcinoma 27 Neoplasms 25 Breast Neoplasms 20 Colorectal Neoplasms 18 Melanoma 15 Triple Negative Breast Neoplasms 14 Urinary Bladder Neoplasms 13 Carcinoma, Transitional Cell 13 Neoplasm Metastasis 12 Carcinoma, Renal Cell 12 Squamous Cell Carcinoma of Head and Neck 10 Prostatic Neoplasms 9 Uterine Cervical Neoplasms 8 Stomach Neoplasms 8 Glioblastoma 8 Endometrial Neoplasms 7 Ovarian Neoplasms 6 Head and Neck Neoplasms 6 Sarcoma 5 Pancreatic Neoplasms 5 Carcinoma, Neuroendocrine 5 Carcinoma, Merkel Cell 5 Liver Neoplasms 4 Kidney Neoplasms 4 Extensive Stage Lung Small Cell Carcinoma 4 Carcinoma 4 Brain Neoplasms 4

Interventions

trifluridine tipiracil drug combination 1 reolysin 1 atezolizumab 1 Gemcitabine 1 Albumin-Bound Paclitaxel 1 130-nm albumin-bound paclitaxel 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Anal Cancer Metastatic × atezolizumab × 1 year × Clear all

NCT07280377 2026-05-19

GOBLET

Oncolytics Biotech

Phase 1/2 Active not recruiting

Gastrointestinal

Anal Cancer Metastatic

Data powered by HemOnc (CC BY 4.0) Colophon ⚡